IL1B and type 2 diabetes mellitus: Since IL-1β can increase the levels of RANKL [230], which is able to increase DPPIV levels [231], we hypothesize that the biological effects exerted by the BlastiMin Complex® could also counteract the detrimental effects of T2DM (Figure 3).